Des amendes et des règlements importants réduisent à peine les revenus des fabricants de médicaments anticancéreux et ne dissuadent pas les infractions

Cancer drugmakers continue to thrive despite repeated legal penalties, according to a new analysis by the International Consortium of Investigative Journalism. Despite billions in fines and settlements, these companies remain largely unscathed financially and show little sign of changing their business practices. This pattern has been evident in multiple jurisdictions, including South Africa, where a tragic case involving two women battling breast cancer highlighted the ongoing challenges of accessing life-saving treatments. In 2013, Tobeka Daki, a 49-year-old health club receptionist from Mdantsane township in South Africa, was diagnosed with breast cancer. Her oncologist recommended a mastectomy, chemotherapy, and Herceptin, a drug manufactured by Roche. However, due to the exorbitant cost, around $36,000 per year, the medication remained out of reach. Daki's condition worsened, and she passed away at home in November 2016 after her cancer spread to her spine. She was 49 years old. Her story resonated deeply with Babalwa Malgas, a 35-year-old single mother and attorney who had recently opened her law firm. Diagnosed with breast cancer shortly before Daki, Malgas found herself drawn into a cause that would become central to her life. The two women, living just five blocks apart, formed an unlikely bond through their shared illness. They discussed the emotional and practical challenges of navigating cancer care, including the difficulty of explaining their situation to potential partners and the fear of undergoing reconstructive surgery. Their conversations often revolved around the desire to protect their children and ensure they could live healthy lives. The pair soon became known as “sisters” in a broader movement advocating for affordable access to cancer medications. Their efforts led to increased collaboration among nonprofit organizations focused on healthcare equity. These groups intensified their pressure on both the South African government and Roche, calling for reforms to patent laws and lower drug prices. Activists organized protests outside Roche’s Johannesburg office, demanding the company reduce the cost of Herceptin, which was roughly equivalent to four times the country’s average household income. Malgas continued her activism even as her own cancer recurred during the campaign. She described the experience as one of learning about corporate greed, particularly within the pharmaceutical sector. While Roche was a focal point of their frustration, Malgas emphasized that the issue extended far beyond a single company. The systemic nature of the problem, she argued, reflected deeper flaws in the global healthcare system. A recent review conducted by the ICIJ examined enforcement actions against cancer drugmakers across 31 countries. The findings revealed a consistent trend: companies frequently face accusations of unethical behavior, yet rarely suffer consequences that significantly impact their profitability. Practices such as manipulating patents to delay generic alternatives, promoting unnecessary higher doses, and leveraging regulatory loopholes have long been part of the industry’s modus operandi. These tactics not only harm individual patients but also place additional burdens on public healthcare systems and taxpayers. The ICIJ’s analysis builds upon previous investigations, including its earlier work on Merck & Co.’s handling of Keytruda, a widely used cancer therapy. That study exposed how Merck maintained high prices for the drug, limiting patient access and slowing the introduction of more affordable alternatives. The current report expands on these concerns by examining a wider range of cases, drawing on data from public records and contributions from watchdog groups such as Public Citizen and Good Jobs First. Among the notable cases included in the review, authorities in seven countries have accused Roche of misleading physicians regarding the efficacy of certain cancer treatments. These allegations underscore the persistent ethical dilemmas faced by the industry. As the ICIJ continues to uncover patterns of misconduct, the implications for patients and healthcare systems grow increasingly clear. The cycle of fines and settlements appears to offer little real deterrent, leaving the question of meaningful reform unanswered.